3 results
To compare ACM at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by SOC in the intent-to-treat (ITT) population of patients with IFD caused by proven IA at any site or probable lower respiratory tract disease (LRTD…
To assess the efficacy of Revita® DMR for improving HbA1c to <= 7% without the need of insulin in subjects with T2D compared to sham.To assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints.
This study consists of the following objections:- To evaluate feasibility, safety, and efficacy of endoscopic DMR Treatment Paradigm 1 (compared to sham)- To evaluate feasibility, safety, and efficacy of re-treatment with DMR at 24 weeks (compared…